Lp(a) doesn't just add risk-it reframes it (often a lifelong, family conversation). The question isn't "should we test?" but how we implement testing so results are clear and actionable @lipidjournal.bsky.social
🔗 lipidjournal.com/article/S193...
@afgciceromd.bsky.social @eassociety.bsky.social
⏳ Only a few hours to go until the launch of the #GBD2023 at the World Health Summit — and the great news is that you can follow it live on YouTube this afternoon 📽️
📅 October 12, 2025 — 16:00 CEST / 14:00 UTC
🔗 www.youtube.com/watch?v=qPOi...
P.S. All 👀 are on The Lancet today! @ihmeuw.bsky.social
Happening Today – Don’t Miss It!
Join the @eassociety.bsky.social webinar at 17:00 CET to explore the latest Lp(a) guidelines with Dr. Koskinas and Prof. @LaleTokgozoglu. Bring your questions and join the live Q&A—we can’t wait to connect with you online 💫
Rego: eas.to/WebSep29Reg
#EASSoMe #CvPrev
Feeling honored to be recognized for the 3rd consecutive year on Stanford University and Elsevier’s Top 2% Scientists list. #Grateful to my incredible colleagues and mentors — thank you for your support as we keep pushing boundaries and growing together @unibo.it @eassociety.bsky.social #CvPrev
Super excited to be selected for the first IAS Inflammation Academy 🌟
Looking forward to learning, sharing ideas, and being inspired by amazing mentors and peers #CvPrev
#EASSoMe @eassociety.bsky.social
🔗https://athero.org/ias-inflammation-academy/
PRESS RELEASE: Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
Detailed results from the pivotal P3 Launch-HTN trial were published today in @jama.com, reinforcing lorundrostat’s efficacy in a real-world setting.
Read our press release to learn more: ir.mineralystx.com/news-events/...
#BloodPressure #Cardiology #Cardiosky #MLYS
Too many children w/ HeFH go undiagnosed. RCPCH has launched 2 🆓 online modules to help paediatricians & HCPs better spot and support them. Let’s close the gap in care #EASSoMe @eassociety.bsky.social
📚 Learn more & take action 👉 learning.rcpch.ac.uk/courses/mana...
🎤 First time speaking at #RiminiWellness — I shared some insights on non-pharmacological strategies for managing dyslipidemia. Thanks for the invitation and the audience’s practical questions! Science & wellness grow stronger together #RW25 #CvPrev
🚨 Heart disease kills 20M+ yearly. Most prevention? Still stuck in the past.
Meet ILEP-SMILE: the 360° strategy tackling not just diet & exercise, but much more!
This isn’t a guideline. It’s a global call to action! 🫀🌍
🔗 www.archivesofmedicalscience.com/A-360-Perspe...
🌐 #INPST #PublicHealth
Had the pleasure of delivering a talk at the ANCE Interprovincial Congress on CV prevention & dyslipidemia management in low-risk patients. Empowering 👫 today means healthier tomorrows—for them and the healthcare system. Grateful for the warm welcome! #EASSoMe @eassociety.bsky.social
Great to have Prof. Jung Hyun Choi with us in Bologna during her journey from South Korea to Milan for the ESH Annual Congress. A meaningful exchange ahead of #ESH2025 — and a perfect occasion to let her try tagliatelle al ragù! 🇮🇹🍝 @afgciceromd.bsky.social @unibo.bsky.social
Novel staging system for systemic metabolic disorders! With actionable treatment
Step zero before lifestyle changes, meds, or surgery? Read the 🆕 EAS Consensus!
🔗https://doi.org/10.1093/eurheartj/ehaf314
Because being clueless isn’t a treatment strategy 😎
#EASSoMe @eassociety.bsky.social @cibiocm.bsky.social
How do we act?
1⃣ Start w/ lifestyle changes—always the foundation
2⃣ Add the right medications when needed
3⃣ In severe cases, consider surgery
It’s not one-size-fits-all: treatment must match the stage and the organs involved #EASSoMe @eassociety.bsky.social
Excess fat can silently damage your liver, 🫀, kidneys, pancreas—not just 📈 your weight.
That’s why early, multi-organ screening is key. Catch risks before they turn into disease - because progression to later stages means a much higher risk of death ⚠️ @eassociety.bsky.social #EASSoMe
📊 Shocking stat: Over 75% of people in the UK Biobank show early signs of systemic metabolic disorders. The new @eassociety.bsky.social staging system (Stage 1–3) helps detect risks early—so we can act before it’s too late. Prevention starts now 🙌 #EASSoMe @cibiocm.bsky.social
The brand-new EAS Consensus is here—offering a game-changing, clinically actionable roadmap to tackle met disorders linked to obesity. Time to move from treating symptoms to a full-body, root-cause approach
@eassociety.bsky.social @cibiocm.bsky.social #EASSoMe
#MyEAS2025 The live discussion of my case on statin intolerance at #EASCongress2025 was truly exciting! The EAS Stage was packed—much more than the photo shows—and the audience was incredibly engaged. Big thanks to everyone who joined for this rewarding discussion! @eassociety.bsky.social
#MyEAS2025 Honored to join as a panelist at #EASCongress2025 in a session on the power of SoMe in science & networking. Sharing how these platforms launched my journey into ath was truly exciting—and I hope it inspires other early-career researchers! @eassociety.bsky.social @katioorni.bsky.social
💡 Key takeaway in one line! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
Excited to share the latest breakthroughs in lipid research and clinical practice. Here’s a quick snapshot of yesterday's late-breaking findings 👇
The BROADWAY study results are out now in @nejm.org, published simultaneously with their presentation at #EASCongress2025 🙌 So if you missed Prof. Nicholls' talk—you can catch up here www.nejm.org/doi/full/10....
#EASCongress2025 #MyEAS2025 @maciejbanach.bsky.social @eassociety.bsky.social
Obicetrapib was well tolerated in the BROADWAY study. Long-term effects on CV outcomes will be evaluated in the ongoing PREVAIL trial—but current results suggest it holds considerable promise for improving lipid control in high CV risk patients #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
BROADWAY Study: Additionally, obicetrapib led to a placebo-adj 33.5% reduction in Lp(a), independent of its effects on other lipid parameters and HDL-C increase. The broader lipid effects are also very encouraging #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
BROADWAY study: Obicetrapib, added to maximally tolerated LLT in high-risk CV patients, reduced placebo-adjusted LDL-C by 32.6% at day 84 and 24% at day 365, with 51% of patients reaching LDL-C <55 mg/dL #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
The results of the TANDEM trial have been published in @thelancet.bsky.social , simultaneously with their presentation at the #EASCongress2025! Read the full article here: doi.org/10.1016/S014...
@erinmichos.bsky.social @eassociety.bsky.social #MyEAS2025
While the TANDEM trial has limitations—short follow-up, mainly White participants, and no systematic CV event tracking—if approved, the fixed-dose combo could still offer a valuable new oral option for lowering LDL-C in patients on maximally tolerated LLT #EASCongress2025 @eassociety.bsky.social
Beyond LDL-C, the TANDEM trial showed very encouraging results on ApoB and a high proportion of patients reaching lipid targets. The fixed-dose combo was also well tolerated #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
The TANDEM trial: the fixed-dose combo of obicetrapib + ezetimibe cut LDL-C by nearly 50%, with over 70% of participants reaching levels below 1.4 mmol/L. A promising step forward in lipid lowering! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
Absolute pleasure to present at #EASCongress2025. Come and find me if you want to talk anything spatial, proteomics or mechanisms of vulnerable plaque! @eassociety.bsky.social
#EASCongress2025 Late Breakers - Key takeaway in one line! #MyEAS2025
Check out the slide below for a one-line summary of each late-breaking presentation — concise, clear, and all in one place 😎 @eassociety.bsky.social